Enlaza Therapeutics, Inc.
Enlaza Therapeutics is pioneering the field of covalent biologics, developing a novel classes of protein therapeutics based on its proprietary War-Lock™ platform.
Funding history
About Enlaza Therapeutics, Inc.
How much funding has Enlaza Therapeutics, Inc. raised?
Enlaza Therapeutics, Inc. has raised $99.0M in total funding. The most recent round was Series A.
Where is Enlaza Therapeutics, Inc. headquartered?
Enlaza Therapeutics, Inc. is headquartered in La Jolla, CA.
What does Enlaza Therapeutics, Inc. do?
Enlaza Therapeutics is pioneering the field of covalent biologics, developing a novel classes of protein therapeutics based on its proprietary War-Lock™ platform.
What problem does Enlaza Therapeutics, Inc. solve?
Standard protein therapeutics bind only reversibly to their targets, requiring long-lasting or continuous dosing that causes sustained exposure to healthy tissue, limiting efficacy and causing toxicity.
What's Enlaza Therapeutics, Inc.'s solution?
Enlaza develops covalent protein biologics, called War-Lock therapeutics, engineered to irreversibly and selectively lock onto disease-related targets.
What makes Enlaza Therapeutics, Inc. different?
Its platform is built on a proprietary unnatural amino acid that enables covalent bond formation only upon target engagement, staying inert while circulating, and can reportedly be incorporated into virtually any protein drug format.
What makes Enlaza Therapeutics, Inc. notable?
San Diego-based Enlaza Therapeutics raised a $100M Series A led by the Life Sciences group of J.P. Morgan Private Capital, with backing from Amgen Ventures and Regeneron.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.